0001551163-16-000325.txt : 20160331 0001551163-16-000325.hdr.sgml : 20160331 20160330200320 ACCESSION NUMBER: 0001551163-16-000325 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160331 DATE AS OF CHANGE: 20160330 EFFECTIVENESS DATE: 20160331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOETHICS LTD CENTRAL INDEX KEY: 0000894560 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 870485312 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-55254-41 FILM NUMBER: 161541394 BUSINESS ADDRESS: STREET 1: 1661 LAKEVIEW CIRCLE CITY: OGDEN STATE: UT ZIP: 84403 BUSINESS PHONE: (801) 399-3632 MAIL ADDRESS: STREET 1: 1661 LAKEVIEW CIRCLE CITY: OGDEN STATE: UT ZIP: 84403 NT 10-K 1 bioethics20151231form12b25v0.htm Converted by EDGARwiz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549


FORM 12b-25


NOTIFICATION OF LATE FILING


(Check one):

[X]  Form 10-K [   ]  Form 20-F [   ]  Form 11-K [   ]  Form 10-Q [   ]  Form 10-D [   ]  Form N-SAR [   ]  Form N-CSR


For Period Ended: December 31, 2015


[   ]  Transition Report on Form 10-K

[   ]  Transition Report on Form 20-F

[   ]  Transition Report on Form 11-K

[   ]  Transition Report on Form 10-Q

[   ]  Transition Report on Form N-SAR

For the Transition Period Ended: _____________________


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification related to a portion of the filing checked above, identify the Item(s) to which the notification relates:


PART I

REGISTRANT INFORMATION


BIOETHICS, LTD.

Full Name of Registrant


_____________________

Former Name if Applicable


1661 Lakeview Circle, Ogden, UT 84403

Address of Principal Executive Office


PART II

RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate).

 

 

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;


 

[X]

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c)

The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.



PART III

NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the prescribed period.

 

The registrant has not finalized its financial statements for the fiscal year ended December 31, 2015, nor has the registrant’s certifying auditors had the opportunity to complete their audit of the financial statements to be included in the Form 10-K.  Accordingly, the registrant cannot complete and file its Form 10-K annual report by the due date, but expects its financial statements and audit will be completed and the Form 10-K finalized in order to file the report within the prescribed extension period.



PART IV

OTHER INFORMATION

 

(1)  Name and telephone number of person to contact in regard to this notification: 


Mark A. Scharmann, President

Name


1-801-399-3632

Telephone Number



(2)  Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).  [X] Yes [  ] No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  [   ] Yes [X] No


If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

Bioethics, LTD. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:

March 30, 2016

/s/ Mark A. Scharmann

 

 

 

 

By:

Mark A. Scharmann

President and CEO